Lung adenocarcinoma remains the predominant histological subtype of non-small cell lung cancer (NSCLC), with epidermal growth factor receptor (EGFR) sensitizing mutations (primarily exon 19 deletions and exon 21 L858R point mutations) identified as critical oncogenic drivers in approximately 10-15% of Caucasian and 40-50% of Asian patients (1, 2). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.